Last updated on September 2007

New Drug That May Protect Function of Reproductive Organs in Girls Receiving Cyclophosphamide for Lupus

Brief description of study

The purpose of this study is to test the safety of triptorelin when used for the protection of the ovaries (pair of female reproductive organs) during cyclophosphamide therapy for systemic lupus erythematosus (SLE; lupus) and to see what effects (good or bad) it has on you. The study will be done with female patients who have been diagnosed with Systemic Lupus Erythematosus, are younger than 21 years of age, and require intravenous cyclophosphamide to control the disease. Each patient will be in the study for approximately 23 months, until 4 months after your intravenous cyclophosphamide treatment has been completed. This study is being conducted at 7 sites across the United States (New York, Chicago, Milwaukee, Columbus, Seattle, Los Angeles, Cincinnati). A total of 50 patients will participate in this study. Each patient will be randomized (assigned) to one of 5 groups. Randomization means that you are put into a group completely by chance. It is like flipping a coin. Neither the patient nor the study staff knows what group the patient is in. The patient has a 20% chance of being placed in any group.

Detailed Study Description

Only females newly requiring cyclophosphamide can participate.

Clinical Study Identifier: NCT00088244

Find a site near you

Start Over